Currently out of the existing stock ratings of Kalpit Patel, 72 are a BUY (72%), 28 are a HOLD (28%).

Kalpit Patel

Work Performance Price Targets & Ratings Chart

Analyst Kalpit Patel, currently employed at B. RILEY, carries an average stock price target met ratio of 45.78% that have a potential upside of 50.82% achieved within 162 days.

Kalpit Patel’s has documented 200 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 23-Oct-2025.

Wall Street Analyst Kalpit Patel

Analyst best performing recommendations are on XFOR (X4 PHARMACEUTICALS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/2/2023. The price target of $16 was fulfilled within 5 days with a profit of $3.92 (32.45%) receiving and performance score of 64.9.

Average potential price target upside

of $12.65 (49.55%) on KYMR (KYMERA THERAPEUTICS).
of $12.05 (55.14%) on INKT (MINK THERAPEUTICS).
of $9.73 (50.96%) on LBPH (LONGBOARD PHARMACEUTICALS).

BCYC Bicycle Therapeutics Ltd INFI Infinity Pharmaceuticals INKT Mink Therapeutics KYMR Kymera Therapeutics MGTA Magenta Therapeutics RIGL Rigel Pharmaceuticals FBRX Forte Biosciences ALLO Allogene Therapeutics ENTX Entera Bio Ltd INAB In8bio VINC Vincerx Pharma MRTX Mirati Ther DERM Journey Medical Corp GERN Geron VRDN Viridian Therapeutics SNDX Syndax Pharmaceuticals LBPH Longboard Pharmaceuticals CRBP Corbus Pharmaceuticals PDSB PDS Biotechnology Corp VSTM Verastem XFOR X4 Pharmaceuticals OVID Ovid Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Reni Benjamin (JMP)